Jul. 2 at 10:09 PM
Gene editing still looks early, and
$VRTX /
$CRSP keep the spotlight on CASGEVY. The first approved CRISPR therapy has already shown real traction in sickle cell, and each new FDA step adds more credibility to the story.
$XBI stays in focus as the sector narrative builds.
